Lumiray 1200 Chemiluminescence Analyzer Lumiray 1600 Chemiluminescence Analyzer Lumiray 600 Chemiluminescence Analyzer 2019-nCoV IgM 2019-nCoVlgG A Detection Solution to COVID-19 Rayto 2019-nCoV IgM and IgG ■ Ordering information Test Principle Chemiluminescence immunoassay (CLIA) 2019-nCoV lgM(50T) Cat. No. S4500471 Sample Type Serum, Plasma 2019-nCoV IgM(IOOT) Cat. No. S4500472 First Result Time 35 minutes 2019-nCoV lgG(50T) Cat. No. S4500473 Sample Volume 10pl 2019-nCoV IgG(IOOT) Cat. No. S4500474 Features • Comprehensive Solution. Rayto provides devices and reagent kits of both IgM and IgG tests for the detection of 2019-nCOV/SARS-CoV-2. • Fully automatic. Low infection risk for operators. • High specificity and high sensitivity. • Quick detection. The test can be finished within 35 minutes. • High throughput. Up to 120T/H. • Joint test solution for COVID-19 and its comorbidities. • Low sample consumption. Rayto reserves the right to change specifications without prior notice. P/N: ENG-COVID-19-20200518 Rayto Life and Analytical Sciences Co., Ltd. Rayto Industrial Building, Shuangming Blvd South, East Hi-Tech Park, Guangming New District, 518107 Shenzhen, P.R.China. Tel: +86 (755) 88832350 Fax: +86 (755) 86168796 Email: [email protected] Web: www.rayto.com

Average sensitivity Average specificity Average sensitivity Average specificity IgM and IgG in COVID-19 Diagnosis In addition to nucleic acid testing, IgM and IgG have been incorporated into the new criteria for non-firmed and ruling out COVID-19 suspected cases (not for general population): • Confirmed COVID-19 infection: An infection is confirmed when serology antibody tests show SARS-CoV-2 IgM and IgG are positive, or SARS-CoV-2 IgG change from negative to positive or is 4 times higher in the recovery period than in the acute phase. • Ruled out COVID-19 suspected cases: A suspected COVID-19...